For details see Note (34) “Equity”.
|
|
|
|
Comprehensive income |
|
|
|
|
|
|
|
|
|
|
||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
€ million |
|
Jan. 1, 2020 |
|
Profit after tax |
|
Gains/ losses recognized in equity |
|
Dividend payments |
|
Profit transfer to/ from E. Merck KG, Darmstadt, Germany including changes in reserves |
|
Transactions with no change of control |
|
Change in scope of consolidation/ Other |
|
Dec. 31, 2020 |
Equity capital |
|
565 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
565 |
General partner’s equity |
|
397 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
397 |
Subscribed capital |
|
168 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
168 |
Capital reserves |
|
3,814 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
3,814 |
Retained earnings |
|
11,483 |
|
1,987 |
|
-357 |
|
-168 |
|
-567 |
|
-1 |
|
– |
|
12,378 |
Retained earnings/net retained profit |
|
13,134 |
|
1,987 |
|
– |
|
-168 |
|
-567 |
|
-1 |
|
68 |
|
14,453 |
Remeasurement of defined benefit plans |
|
-1,729 |
|
– |
|
-473 |
|
– |
|
– |
|
– |
|
23 |
|
-2,179 |
Fair value reserve for equity instruments |
|
79 |
|
– |
|
116 |
|
– |
|
– |
|
– |
|
-91 |
|
105 |
Gains/losses recognized in equity |
|
1,980 |
|
– |
|
-1,790 |
|
– |
|
– |
|
– |
|
– |
|
189 |
Fair value reserve for debt instruments |
|
-1 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
Cash flow hedge reserve |
|
-118 |
|
– |
|
69 |
|
– |
|
– |
|
– |
|
– |
|
-49 |
Cost of cash flow hedge reserve |
|
-33 |
|
– |
|
-1 |
|
– |
|
– |
|
– |
|
– |
|
-34 |
Currency translation difference |
|
2,131 |
|
– |
|
-1,859 |
|
– |
|
– |
|
– |
|
– |
|
273 |
Equity attributable to shareholders of Merck KGaA, Darmstadt, Germany |
|
17,841 |
|
1,987 |
|
-2,147 |
|
-168 |
|
-567 |
|
-1 |
|
– |
|
16,946 |
Non-controlling interests |
|
73 |
|
7 |
|
-2 |
|
-7 |
|
– |
|
– |
|
– |
|
71 |
Total equity |
|
17,914 |
|
1,994 |
|
-2,149 |
|
-175 |
|
-567 |
|
-1 |
|
– |
|
17,017 |
|
|
|
|
Comprehensive income |
|
|
|
|
|
|
|
|
|
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
€ million |
|
Jan. 1, 2019 |
|
Profit after tax |
|
Gains/ losses recognized in equity |
|
Dividend payments |
|
Profit transfer to/ from E. Merck KG, Darmstadt, Germany including changes in reserves |
|
Transactions with no change of control |
|
Change in scope of consolidation/ Other |
|
Dec. 31, 2019 |
||||
Equity capital |
|
565 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
565 |
||||
General partner’s equity |
|
397 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
397 |
||||
Subscribed capital |
|
168 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
168 |
||||
Capital reserves |
|
3,814 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
3,814 |
||||
Retained earnings1 |
|
11,192 |
|
1,320 |
|
-312 |
|
-162 |
|
-510 |
|
– |
|
-45 |
|
11,483 |
||||
Retained earnings/net retained profit1 |
|
12,525 |
|
1,320 |
|
– |
|
-162 |
|
-510 |
|
– |
|
-40 |
|
13,134 |
||||
Remeasurement of defined benefit plans |
|
-1,340 |
|
– |
|
-388 |
|
– |
|
– |
|
– |
|
-2 |
|
-1,729 |
||||
Fair value reserve for equity instruments |
|
7 |
|
– |
|
76 |
|
– |
|
– |
|
– |
|
-4 |
|
79 |
||||
Gains/losses recognized in equity |
|
1,629 |
|
– |
|
350 |
|
– |
|
– |
|
– |
|
– |
|
1,980 |
||||
Fair value reserve for debt instruments |
|
-1 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
-1 |
||||
Cash flow hedge reserve |
|
-128 |
|
– |
|
9 |
|
– |
|
– |
|
– |
|
– |
|
-118 |
||||
Cost of cash flow hedge reserve |
|
-33 |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
-33 |
||||
Currency translation difference |
|
1,790 |
|
– |
|
341 |
|
– |
|
– |
|
– |
|
– |
|
2,131 |
||||
Equity attributable to shareholders of Merck KGaA, Darmstadt, Germany1 |
|
17,200 |
|
1,320 |
|
39 |
|
-162 |
|
-510 |
|
– |
|
-45 |
|
17,841 |
||||
Non-controlling interests1 |
|
33 |
|
3 |
|
2 |
|
-12 |
|
– |
|
– |
|
45 |
|
73 |
||||
Total equity |
|
17,233 |
|
1,324 |
|
41 |
|
-173 |
|
-510 |
|
– |
|
– |
|
17,914 |
||||
|
||||||||||||||||||||